Vaccination with Plasmodium vivax Duffy-binding protein inhibits parasite growth during controlled human malaria infection
There are no licensed vaccines against Plasmodium vivax. We conducted two phase 1/2a clinical trials to assess two vaccines targeting P. vivax Duffy-binding protein region II (PvDBPII). Recombinant viral vaccines using chimpanzee adenovirus 63 (ChAd63) and modified vaccinia virus Ankara (MVA) vectors as well as a protein and adjuvant formulation (PvDBPII/Matrix-M) were tested in both a standard and a delayed dosing regimen. Volunteers underwent controlled human malaria infection (CHMI) after their last vaccination, alongside unvaccinated controls. Efficacy was assessed by comparisons of parasite multiplication rates in the blood. PvDBPII/Matrix-M, given in a delayed dosing regimen, elicited the highest antibody responses and reduced the mean parasite multiplication rate after CHMI by 51% (n = 6) compared with unvaccinated controls (n = 13), whereas no other vaccine or regimen affected parasite growth. Both viral-vectored and protein vaccines were well tolerated and elicited expected, short-lived adverse events. Together, these results support further clinical evaluation of the PvDBPII/Matrix-M P. vivax vaccine.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Science translational medicine - 15(2023), 704 vom: 12. Juli, Seite eadf1782 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 14.07.2023 Date Revised 30.09.2023 published: Print-Electronic UpdateOf: medRxiv. 2022 May 30;:. - PMID 35664997 Citation Status MEDLINE |
|---|
| doi: |
10.1126/scitranslmed.adf1782 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359378617 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359378617 | ||
| 003 | DE-627 | ||
| 005 | 20231226080737.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1126/scitranslmed.adf1782 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1197.xml |
| 035 | |a (DE-627)NLM359378617 | ||
| 035 | |a (NLM)37437014 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hou, Mimi M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Vaccination with Plasmodium vivax Duffy-binding protein inhibits parasite growth during controlled human malaria infection |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.07.2023 | ||
| 500 | |a Date Revised 30.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a UpdateOf: medRxiv. 2022 May 30;:. - PMID 35664997 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a There are no licensed vaccines against Plasmodium vivax. We conducted two phase 1/2a clinical trials to assess two vaccines targeting P. vivax Duffy-binding protein region II (PvDBPII). Recombinant viral vaccines using chimpanzee adenovirus 63 (ChAd63) and modified vaccinia virus Ankara (MVA) vectors as well as a protein and adjuvant formulation (PvDBPII/Matrix-M) were tested in both a standard and a delayed dosing regimen. Volunteers underwent controlled human malaria infection (CHMI) after their last vaccination, alongside unvaccinated controls. Efficacy was assessed by comparisons of parasite multiplication rates in the blood. PvDBPII/Matrix-M, given in a delayed dosing regimen, elicited the highest antibody responses and reduced the mean parasite multiplication rate after CHMI by 51% (n = 6) compared with unvaccinated controls (n = 13), whereas no other vaccine or regimen affected parasite growth. Both viral-vectored and protein vaccines were well tolerated and elicited expected, short-lived adverse events. Together, these results support further clinical evaluation of the PvDBPII/Matrix-M P. vivax vaccine | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Intramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 700 | 1 | |a Barrett, Jordan R |e verfasserin |4 aut | |
| 700 | 1 | |a Themistocleous, Yrene |e verfasserin |4 aut | |
| 700 | 1 | |a Rawlinson, Thomas A |e verfasserin |4 aut | |
| 700 | 1 | |a Diouf, Ababacar |e verfasserin |4 aut | |
| 700 | 1 | |a Martinez, Francisco J |e verfasserin |4 aut | |
| 700 | 1 | |a Nielsen, Carolyn M |e verfasserin |4 aut | |
| 700 | 1 | |a Lias, Amelia M |e verfasserin |4 aut | |
| 700 | 1 | |a King, Lloyd D W |e verfasserin |4 aut | |
| 700 | 1 | |a Edwards, Nick J |e verfasserin |4 aut | |
| 700 | 1 | |a Greenwood, Nicola M |e verfasserin |4 aut | |
| 700 | 1 | |a Kingham, Lucy |e verfasserin |4 aut | |
| 700 | 1 | |a Poulton, Ian D |e verfasserin |4 aut | |
| 700 | 1 | |a Khozoee, Baktash |e verfasserin |4 aut | |
| 700 | 1 | |a Goh, Cyndi |e verfasserin |4 aut | |
| 700 | 1 | |a Hodgson, Susanne H |e verfasserin |4 aut | |
| 700 | 1 | |a Mac Lochlainn, Dylan J |e verfasserin |4 aut | |
| 700 | 1 | |a Salkeld, Jo |e verfasserin |4 aut | |
| 700 | 1 | |a Guillotte-Blisnick, Micheline |e verfasserin |4 aut | |
| 700 | 1 | |a Huon, Christèle |e verfasserin |4 aut | |
| 700 | 1 | |a Mohring, Franziska |e verfasserin |4 aut | |
| 700 | 1 | |a Reimer, Jenny M |e verfasserin |4 aut | |
| 700 | 1 | |a Chauhan, Virander S |e verfasserin |4 aut | |
| 700 | 1 | |a Mukherjee, Paushali |e verfasserin |4 aut | |
| 700 | 1 | |a Biswas, Sumi |e verfasserin |4 aut | |
| 700 | 1 | |a Taylor, Iona J |e verfasserin |4 aut | |
| 700 | 1 | |a Lawrie, Alison M |e verfasserin |4 aut | |
| 700 | 1 | |a Cho, Jee-Sun |e verfasserin |4 aut | |
| 700 | 1 | |a Nugent, Fay L |e verfasserin |4 aut | |
| 700 | 1 | |a Long, Carole A |e verfasserin |4 aut | |
| 700 | 1 | |a Moon, Robert W |e verfasserin |4 aut | |
| 700 | 1 | |a Miura, Kazutoyo |e verfasserin |4 aut | |
| 700 | 1 | |a Silk, Sarah E |e verfasserin |4 aut | |
| 700 | 1 | |a Chitnis, Chetan E |e verfasserin |4 aut | |
| 700 | 1 | |a Minassian, Angela M |e verfasserin |4 aut | |
| 700 | 1 | |a Draper, Simon J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Science translational medicine |d 2009 |g 15(2023), 704 vom: 12. Juli, Seite eadf1782 |w (DE-627)NLM195151879 |x 1946-6242 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2023 |g number:704 |g day:12 |g month:07 |g pages:eadf1782 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1126/scitranslmed.adf1782 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2023 |e 704 |b 12 |c 07 |h eadf1782 | ||